Results of the association of intralesional recombinant alpha interferon- 2a (α-IFN) plus 13-cis-retinoic acid (13cRA) in the treatment of basal cell carcinomas (BCC) of the skin

S. Toma, M. Vincenti, R. Palumbo, G. Muzio, M. L. Rainero, P. Santi, R. Rosso

Research output: Contribution to journalArticlepeer-review

Abstract

In this phase II study, twenty-four patients (median age 72 years) with BCC of the skin were treated with intralesional α-IFN plus 13cRA. α-IFN was administered intralesionally at the dose of 3x106 I.U. for injection, 3 times/week for 4 weeks (total dose 12x106 I.U./cycle); concomitantly, 13cRA was given per os at a 0.2-0.4 mg/kg/day dose. The 4-week cycles were repeated after a one week interval, in which only 13cRA was administered. Patients were evaluated after at least 2 cycles of treatment. Sixteen of the 20 assessable patients (80%) showed an objective response (OR), 12 of whom (60%) had a complete response (CR). The overall OR rate was 75% (12/16) in patients treated with 0.2 mg/kg/day of 13cRA, and 100% (4/4) in patients who received 0.4 mg/kg/day of the drug. The median response duration was 12 months (range, 6 to 20). Toxicity was mild and reversible in all cases; major side effects observed were fever, nausea, skin erythema, hypertriglyceridemia and hypercholesteremia. These results show the efficacy and the feasibility of α-IFN and 13cRA acid association in BCC treatment, with good compliance even in elderly patients; this medical approach could be a valid choice of therapy in addition to the traditional surgical modalities, as it also produces satisfactory aesthetical results.

Original languageEnglish
Pages (from-to)1149-1154
Number of pages6
JournalInternational Journal of Oncology
Volume3
Issue number6
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Results of the association of intralesional recombinant alpha interferon- 2a (α-IFN) plus 13-cis-retinoic acid (13cRA) in the treatment of basal cell carcinomas (BCC) of the skin'. Together they form a unique fingerprint.

Cite this